258 related articles for article (PubMed ID: 21306770)
1. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.
Lim SM; Kim TH; Jiang HH; Park CW; Lee S; Chen X; Lee KC
Biomaterials; 2011 May; 32(13):3538-46. PubMed ID: 21306770
[TBL] [Abstract][Full Text] [Related]
2. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.
Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC
J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635
[TBL] [Abstract][Full Text] [Related]
3. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.
Jiang HH; Kim TH; Lee S; Chen X; Youn YS; Lee KC
Biomaterials; 2011 Nov; 32(33):8529-37. PubMed ID: 21855130
[TBL] [Abstract][Full Text] [Related]
4. Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis.
Kim YJ; Chae SY; Jin CH; Sivasubramanian M; Son S; Choi KY; Jo DG; Kim K; Chan Kwon I; Lee KC; Park JH
Biomaterials; 2010 Dec; 31(34):9057-64. PubMed ID: 20813405
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
Bae S; Ma K; Kim TH; Lee ES; Oh KT; Park ES; Lee KC; Youn YS
Biomaterials; 2012 Feb; 33(5):1536-46. PubMed ID: 22118776
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution.
Kim TH; Jiang HH; Youn YS; Park CW; Lim SM; Jin CH; Tak KK; Lee HS; Lee KC
J Pharm Sci; 2011 Feb; 100(2):482-91. PubMed ID: 20669330
[TBL] [Abstract][Full Text] [Related]
7. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors.
Jiang X; Sha X; Xin H; Chen L; Gao X; Wang X; Law K; Gu J; Chen Y; Jiang Y; Ren X; Ren Q; Fang X
Biomaterials; 2011 Dec; 32(35):9457-69. PubMed ID: 21911250
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation.
Yang A; Yang L; Liu W; Li Z; Xu H; Yang X
Int J Pharm; 2007 Feb; 331(1):123-32. PubMed ID: 17097246
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.
Huang S; Li J; Han L; Liu S; Ma H; Huang R; Jiang C
Biomaterials; 2011 Oct; 32(28):6832-8. PubMed ID: 21700333
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique.
Zhang C; Li G; Wang Y; Cui F; Zhang J; Huang Q
Int J Pharm; 2012 Oct; 436(1-2):272-81. PubMed ID: 22721846
[TBL] [Abstract][Full Text] [Related]
11. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects.
Kim TH; Youn YS; Jiang HH; Lee S; Chen X; Lee KC
Bioconjug Chem; 2011 Aug; 22(8):1631-7. PubMed ID: 21751817
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the targeting capabilities of the Paclitaxel-loaded pluronic nanoparticles with a glycol chitosan/heparin composite.
Yuk SH; Oh KS; Cho SH; Kim SY; Oh S; Lee JH; Kim K; Kwon IC
Mol Pharm; 2012 Feb; 9(2):230-6. PubMed ID: 22149139
[TBL] [Abstract][Full Text] [Related]
13. Target-specific cellular uptake of taxol-loaded heparin-PEG-folate nanoparticles.
Wang Y; Wang Y; Xiang J; Yao K
Biomacromolecules; 2010 Dec; 11(12):3531-8. PubMed ID: 21086982
[TBL] [Abstract][Full Text] [Related]
14. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
[TBL] [Abstract][Full Text] [Related]
15. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
Pan LQ; Wang HB; Lai J; Xu YC; Zhang C; Chen SQ
Biomaterials; 2013 Dec; 34(36):9115-23. PubMed ID: 23981355
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
17. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
18. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo.
Choi KY; Min KH; Yoon HY; Kim K; Park JH; Kwon IC; Choi K; Jeong SY
Biomaterials; 2011 Mar; 32(7):1880-9. PubMed ID: 21159377
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo.
Zhan C; Wei X; Qian J; Feng L; Zhu J; Lu W
J Control Release; 2012 Jun; 160(3):630-6. PubMed ID: 22410115
[TBL] [Abstract][Full Text] [Related]
20. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors.
Luo G; Yu X; Jin C; Yang F; Fu D; Long J; Xu J; Zhan C; Lu W
Int J Pharm; 2010 Jan; 385(1-2):150-6. PubMed ID: 19825404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
